As part of the Company’s strategic focus on developing controlled release formulations for clients, OctoPlus N.V. (“OctoPlus” or “the Company”) (Euronext: OCTO) announces today that it has signed a new drug delivery technology evaluation contract with a European biotech company. This is the seventh client for which OctoPlus will work on a controlled release formulation.

In October last year OctoPlus announced a strategic focus on developing controlled release versions of existing or new drugs for clients, in addition to providing general formulation development and clinical material manufacturing.

Under the contract announced today, OctoPlus will evaluate the feasibility of a controlled release formulation that combines the active ingredient of the client with OctoPlus’ proprietary drug delivery technology. If the evaluation is successful, the contract may progress to a full process development, manufacturing and licensing agreement.

For further information, please contact:
Rianne Roukema, Corporate Communications, telephone number +31 (71) 524 1071 or e-mail IR@octoplus.nl.
d.d. 13 aug. 2012.